ABOS
Acumen Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Acumen Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
No other changes.
No other changes.
No thesis.
No trades yet today.
No trades yet today.
Acumen Pharmaceuticals, Inc.
0.22
pre 0.22 +2.64%
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $56.1M | 43.81% | 0.00% |
| Sands Capital Ventures | $9.9M | 7.76% | 0.00% |
| BlackRockindex-like | $6.6M | 5.20% | +1296.38% |
| Alyeska Investment | $6.6M | 5.12% | 0.00% |
| Franklin Resources | $6.2M | 4.81% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $56.1M | 43.81% | 0.00% |
| Sands Capital Ventures | $9.9M | 7.76% | 0.00% |
| BlackRockindex-like | $6.6M | 5.20% | +1296.38% |
| Alyeska Investment | $6.6M | 5.12% | 0.00% |
| Franklin Resources | $6.2M | 4.81% | 0.00% |
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Acumen Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Acumen Pharmaceuticals, Inc..
Expected move
No implied move.
Bull3
Bear1
Tall tick = annual report · Source: EDGAR
News
Linked news
—